Treatment of Hepatitis C with Milk Thistle?

References

• Cheney C P, Chopra S, Graham C. Hepatitis C. Infect Dis Clin North Amer 2000; 14(3)633–667
   PubMed Web of Science ®Google Scholar
• Alter M J. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341(8)556–562
   PubMed Web of Science ®Google Scholar
• Alter M J. Epidemiology of hepatitis C in the west. Semin Liver Dis 1995; 15: 5–14
   PubMed Web of Science ®Google Scholar
• Hoofnagle J H. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26: 15S–20S
   PubMed Web of Science ®Google Scholar
• Di Bisceglie A M. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26: 34S–38S
   PubMed Web of Science ®Google Scholar
• Poynard T, Marcellin P, Lee S S, et al. Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998; 352: 1426–1436
   PubMed Web of Science ®Google Scholar
• McHutchison J G, Gordon S C, Schiff E R, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485–1492
   PubMed Web of Science ®Google Scholar
• Flora K D, Rosen H R, Benner K G. The use of naturopathic remedies for chronic liver disease. Amer J Gastroenterol 1996; 91(12)2654–2655
   PubMed Web of Science ®Google Scholar
• Peyton B G, Spears T L, Lindsey A, et al. A survey of the use of herbal medicine in patients with hepatitis C. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases, Dallas, Texas, November, 5–91999, Abstract 123. http://www.medscape.com/medscape/CNO/1999/AASLD/AASLD.10.html. Accessed 11/15/00.
   Google Scholar
• Jensen D M, Ganger D R, Cotler S J, et al. Herbal and vitamin/mineral supplement use during antiviral therapy for hepatitis C. Program and abstracts of the 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases, Dallas, Texas, November, 5–91999, Abstract 130. http://www.medscape.com/medscape/CNO/1999/AASLD/AASLD.10.html. Accessed 11/15/00.
   Google Scholar
• Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am Coll Gastroenterol 1998; 93(2)139–143
   PubMed Web of Science ®Google Scholar
• Foster S. Milk Thistle. Silybum marianum. The American Botanical Council, Austin, TX 1996
   Google Scholar
• Luper S. A review of plants used in the treatment of liver disease: part 1. Altern Med Rev 1998; 3(6)410–421
   PubMedGoogle Scholar
• Robbers J E, Tyler V E. Tyler’s Herbs of Choice. The Therapeutic Use ofPhy-tomedicinals. The Haworth Herbal Press, New York, NY 1999
   Google Scholar
• Hammouda F M, Ismall S I, Hassan N M, et al. Evaluation of the silymarin content in Silybum marianum cultivated under different agricultural conditions. Planta Med 1991; 57(Suppl 2)A29
   PubMedGoogle Scholar
• Herbal Medicine. Expanded Commission E Monographs, M Blumenthal. Integrative Medicine Communications, Newton, MA 2000
   Google Scholar
• Anon. Silybum marianum (milk thistle). Altern Med Rev 1999; 4(4)272–274
   PubMedGoogle Scholar
• Schulz V, Hansel R, Tyler V E. Rational Phytotherapy: A Physician’s Guide to Herbal Medicine. 3rd ed. Springer-Verlag, BerlinGermany 1998
   Google Scholar
• Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patient. Arzneimittelforschung 1992; 42: 964–968
   PubMed Web of Science ®Google Scholar
• Herbal Medicinals. A Clinician’s Guide, L G Miller, W J Murray. Pharmaceutical Products Press, New York, NY 1998
   Google Scholar
• Allain H, Schuck S, Lebreton S, et al. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 1999; 10: 181–185
   PubMed Web of Science ®Google Scholar
• La Grange L, Wang M, Watkins R, et al. Protective effects of the flavonoid mixture, silymarin, on fetal rat brain and liver. J Ethnopharmacol 1999; 65: 53–61
   PubMed Web of Science ®Google Scholar
• Albrecht M., Frerick H, Huhn U, et al. Therapy of toxic liver pathologies with Legalon. Z Klin Med 1992; 47(2)87–92
   Google Scholar
• Hobbs C. Milk Thistle. The Liver Herb. 2nd edition. Botanica Press, Santa Cruz, CA 1992
   Google Scholar
• Salmi H A, Sarna S. Effect of silymarin on chemical, functional and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol 1982; 17(4)517–523
   PubMed Web of Science ®Google Scholar
• Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B. Randomized controlled trial of silymarin treatment in patient with cirrhosis of the liver. J Hepatol 1989; 9(1)105–113
   PubMed Web of Science ®Google Scholar
• Trinchet J C, Coste T, Levy V G, Vivet F, Duchatelle V, Legendre C, Gotheil C, Beaugrand M. Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients. Gastroenterol Clin Biol 1989; 13(2)120–124
   PubMed Web of Science ®Google Scholar
• Magliuto E, Gagliardi B, Fiori G P. Result of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres. Med Klin 1978; 73: 1060–1065
   PubMed Web of Science ®Google Scholar
• Berenguer J, Carrasco D. Double-blind trial of silymarin vs placebo in the treatment of chronic hepatitis. Munch Med Wochenschr 1977; 119: 240–260
   Google Scholar
• Bode J C, Schmidt U, Durr H K. Silymarin for the treatment of acute viral hepatitis? Report of a controlled trial. Med Klin 1977; 72: 513–518
   PubMed Web of Science ®Google Scholar
• Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico M. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxciol 1993; 31(9)456–460
   PubMed Web of Science ®Google Scholar
• Lirussi F, Okolicsanyi L. Cytoprotection in the nineties: experience with urso-deoxycholic acid and silymarin in chronic liver disease. Acta Physiol Hung 1992; 80(1–4)363–367
   PubMed Web of Science ®Google Scholar
• Pares A, Planas R, Torres M, et al. The effect of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind randomized and multicenter trial. J Hepatol 1998; 28: 615–621
   PubMed Web of Science ®Google Scholar
• Berkson B M. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. Med Klin 1999; 94(Suppl 3)84–89
   Google Scholar
• Anon. Adverse Drug Reactions Advisory Committee. An adverse reaction to the herbal medication milk thistle (Silybum marianum). Med J Australia 1999; 170: 218–219
   PubMedGoogle Scholar
• Baer-Dubowsk W, Szaefer H, Krajka-Kuzniak V. Inhibition of murine hepatic cytochrome P450 activities by natural and synthetic phenolic compounds. Xenobioti-ca 1998; 28: 735–743
   PubMed Web of Science ®Google Scholar
• Miguez M P, Anundi I, Sainz-Pardo L A. Hepatoprotective mechanism of sily-marin: no evidence for involvement of cytochrome P450 2E1. Chem Biol Interact 1994; 91: 51–63
   PubMed Web of Science ®Google Scholar
• Leber H W, Krauff S. Influence of silymarin on drug metabolizing enzymes in rat and man. Arzheimittelforschung 1976; 26: 1603–1605
   PubMed Web of Science ®Google Scholar
• Palasciano G, Portinacasa P, Palmieri V, et al. The effect of silymarin on plasma levels of malondialdehyde in patients recieving long-term treatment with psycho-tropic drugs. Curr Ther Res 1994; 55: 537–545
   Google Scholar
• Fintelmann V. Toxic metabolic liver damage and its treatment. Z Phytother 1986, 3: 65–73
   Google Scholar
• Blumenthal M. Interactions between herbs and conventional drugs: introductory considerations. HerbalGram 2000; 49: 52–63
   Google Scholar
• Kim D H, Jin Y H, Park J B, Kobashi K. Silymarin and its components are inhibitors of beta-glucuronidase. Biol Pharm Bull 1994; 17: 443–445
   PubMed Web of Science ®Google Scholar
• Anon. Hepatitis C: treatment alternative. National Institutes of Health, National Center for Complementary and Alternative Medicine (NCCAM). NCCAM Clearinghouse. http://nccam.nccam/fcp/factsheets/hepatitis/hepatitisc.htm. Accessed 11/14/00
   Google Scholar